Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression

Michael E. Thase, A. John Rush, Robert H. Howland, Susan G. Kornstein, James H. Kocsis, Alan J. Gelenberg, Alan F. Schatzberg, Lorrin M. Koran, Martin B. Keller, James M. Russell, Robert M A Hirschfeld, Lisa M. LaVange, Daniel N. Klein, Jan Fawcett, Wilma Harrison

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Background: Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has been published that examines prospectively the use of switching to an alternate antidepressant. Methods: This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed to respond to 12 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydrochloride (n = 51), were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication. Outcome measures included the 24-item Hamilton Rating Scale for Depression and the Clinical Global Impressions-Severity and Improvement scales. Results: The switch from sertraline to imipramine (mean dosage, 221 mg/d) and from imipramine to sertraline (mean dosage, 163 mg/d) resulted in clinically and statistically significant improvements. The switch to sertraline treatment was associated with fewer adverse effect complaints and significantly less attrition owing to adverse effects. Although sertraline treatment also resulted in significantly higher response rates in the intent-to-treat samples (60% in the sertraline group and 44% in the imipramine group), neither the intent-to-treat remission rates nor the response and remission rates among study completers differed significantly. Moreover, after considering the effect of attrition, there were no significant treatment effects on the more comprehensive generalized estimating equation analyses of the continuous dependent measures. Conclusions: More than 50% of chronically depressed antidepressant nonresponders benefited from a switch from imipramine to sertraline, or vice versa, despite a high degree of chronicity. As in the initial trial, sertraline was generally better tolerated than imipramine. Switching to a standard antidepressant of a different class is a useful treatment strategy for antidepressant nonresponders and could be considered a standard of comparison for future studies of novel alternate strategies.

Original languageEnglish (US)
Pages (from-to)233-239
Number of pages7
JournalArchives of General Psychiatry
Volume59
Issue number3
StatePublished - 2002

Fingerprint

Sertraline
Imipramine
Double-Blind Method
Antidepressive Agents
Therapeutics
Outpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Thase, M. E., John Rush, A., Howland, R. H., Kornstein, S. G., Kocsis, J. H., Gelenberg, A. J., ... Harrison, W. (2002). Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry, 59(3), 233-239.

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. / Thase, Michael E.; John Rush, A.; Howland, Robert H.; Kornstein, Susan G.; Kocsis, James H.; Gelenberg, Alan J.; Schatzberg, Alan F.; Koran, Lorrin M.; Keller, Martin B.; Russell, James M.; Hirschfeld, Robert M A; LaVange, Lisa M.; Klein, Daniel N.; Fawcett, Jan; Harrison, Wilma.

In: Archives of General Psychiatry, Vol. 59, No. 3, 2002, p. 233-239.

Research output: Contribution to journalArticle

Thase, ME, John Rush, A, Howland, RH, Kornstein, SG, Kocsis, JH, Gelenberg, AJ, Schatzberg, AF, Koran, LM, Keller, MB, Russell, JM, Hirschfeld, RMA, LaVange, LM, Klein, DN, Fawcett, J & Harrison, W 2002, 'Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression', Archives of General Psychiatry, vol. 59, no. 3, pp. 233-239.
Thase ME, John Rush A, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry. 2002;59(3):233-239.
Thase, Michael E. ; John Rush, A. ; Howland, Robert H. ; Kornstein, Susan G. ; Kocsis, James H. ; Gelenberg, Alan J. ; Schatzberg, Alan F. ; Koran, Lorrin M. ; Keller, Martin B. ; Russell, James M. ; Hirschfeld, Robert M A ; LaVange, Lisa M. ; Klein, Daniel N. ; Fawcett, Jan ; Harrison, Wilma. / Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. In: Archives of General Psychiatry. 2002 ; Vol. 59, No. 3. pp. 233-239.
@article{37a3075d83b74fd19220eaf356aae346,
title = "Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression",
abstract = "Background: Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has been published that examines prospectively the use of switching to an alternate antidepressant. Methods: This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed to respond to 12 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydrochloride (n = 51), were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication. Outcome measures included the 24-item Hamilton Rating Scale for Depression and the Clinical Global Impressions-Severity and Improvement scales. Results: The switch from sertraline to imipramine (mean dosage, 221 mg/d) and from imipramine to sertraline (mean dosage, 163 mg/d) resulted in clinically and statistically significant improvements. The switch to sertraline treatment was associated with fewer adverse effect complaints and significantly less attrition owing to adverse effects. Although sertraline treatment also resulted in significantly higher response rates in the intent-to-treat samples (60{\%} in the sertraline group and 44{\%} in the imipramine group), neither the intent-to-treat remission rates nor the response and remission rates among study completers differed significantly. Moreover, after considering the effect of attrition, there were no significant treatment effects on the more comprehensive generalized estimating equation analyses of the continuous dependent measures. Conclusions: More than 50{\%} of chronically depressed antidepressant nonresponders benefited from a switch from imipramine to sertraline, or vice versa, despite a high degree of chronicity. As in the initial trial, sertraline was generally better tolerated than imipramine. Switching to a standard antidepressant of a different class is a useful treatment strategy for antidepressant nonresponders and could be considered a standard of comparison for future studies of novel alternate strategies.",
author = "Thase, {Michael E.} and {John Rush}, A. and Howland, {Robert H.} and Kornstein, {Susan G.} and Kocsis, {James H.} and Gelenberg, {Alan J.} and Schatzberg, {Alan F.} and Koran, {Lorrin M.} and Keller, {Martin B.} and Russell, {James M.} and Hirschfeld, {Robert M A} and LaVange, {Lisa M.} and Klein, {Daniel N.} and Jan Fawcett and Wilma Harrison",
year = "2002",
language = "English (US)",
volume = "59",
pages = "233--239",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression

AU - Thase, Michael E.

AU - John Rush, A.

AU - Howland, Robert H.

AU - Kornstein, Susan G.

AU - Kocsis, James H.

AU - Gelenberg, Alan J.

AU - Schatzberg, Alan F.

AU - Koran, Lorrin M.

AU - Keller, Martin B.

AU - Russell, James M.

AU - Hirschfeld, Robert M A

AU - LaVange, Lisa M.

AU - Klein, Daniel N.

AU - Fawcett, Jan

AU - Harrison, Wilma

PY - 2002

Y1 - 2002

N2 - Background: Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has been published that examines prospectively the use of switching to an alternate antidepressant. Methods: This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed to respond to 12 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydrochloride (n = 51), were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication. Outcome measures included the 24-item Hamilton Rating Scale for Depression and the Clinical Global Impressions-Severity and Improvement scales. Results: The switch from sertraline to imipramine (mean dosage, 221 mg/d) and from imipramine to sertraline (mean dosage, 163 mg/d) resulted in clinically and statistically significant improvements. The switch to sertraline treatment was associated with fewer adverse effect complaints and significantly less attrition owing to adverse effects. Although sertraline treatment also resulted in significantly higher response rates in the intent-to-treat samples (60% in the sertraline group and 44% in the imipramine group), neither the intent-to-treat remission rates nor the response and remission rates among study completers differed significantly. Moreover, after considering the effect of attrition, there were no significant treatment effects on the more comprehensive generalized estimating equation analyses of the continuous dependent measures. Conclusions: More than 50% of chronically depressed antidepressant nonresponders benefited from a switch from imipramine to sertraline, or vice versa, despite a high degree of chronicity. As in the initial trial, sertraline was generally better tolerated than imipramine. Switching to a standard antidepressant of a different class is a useful treatment strategy for antidepressant nonresponders and could be considered a standard of comparison for future studies of novel alternate strategies.

AB - Background: Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has been published that examines prospectively the use of switching to an alternate antidepressant. Methods: This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed to respond to 12 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydrochloride (n = 51), were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication. Outcome measures included the 24-item Hamilton Rating Scale for Depression and the Clinical Global Impressions-Severity and Improvement scales. Results: The switch from sertraline to imipramine (mean dosage, 221 mg/d) and from imipramine to sertraline (mean dosage, 163 mg/d) resulted in clinically and statistically significant improvements. The switch to sertraline treatment was associated with fewer adverse effect complaints and significantly less attrition owing to adverse effects. Although sertraline treatment also resulted in significantly higher response rates in the intent-to-treat samples (60% in the sertraline group and 44% in the imipramine group), neither the intent-to-treat remission rates nor the response and remission rates among study completers differed significantly. Moreover, after considering the effect of attrition, there were no significant treatment effects on the more comprehensive generalized estimating equation analyses of the continuous dependent measures. Conclusions: More than 50% of chronically depressed antidepressant nonresponders benefited from a switch from imipramine to sertraline, or vice versa, despite a high degree of chronicity. As in the initial trial, sertraline was generally better tolerated than imipramine. Switching to a standard antidepressant of a different class is a useful treatment strategy for antidepressant nonresponders and could be considered a standard of comparison for future studies of novel alternate strategies.

UR - http://www.scopus.com/inward/record.url?scp=0036197445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036197445&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 233

EP - 239

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 3

ER -